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Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Over 46 million
people suffer from dementia, with AD accounting for 60-80% of the cases and this
number is expected to double every twenty years [1]. This means that about every 3
seconds, a new case of dementia will be diagnosed worldwide. By 2050, over 130 million
people are expected to suffer from dementia, of which around 90 million will have AD.
The societal burden of AD is especially high, since not only the patient who has the
dementia is affected, but also family and friends, and society as a whole by providing care
and loss of productivity. In general, dementia patients require more intensive care than
patients from other diseases, and the costs for dementia are higher than the combined
costs for cancer, heart disease and stroke [2]. In addition, cognitive impairment, a
symptom of dementia, is the strongest prediction for transition of elderly people to a
care home [3].
In terms of economic value, the global cost of dementia exceeds 800 billion US$,
which accounts for over 1% of global gross domestic product (GDP). A minority of
these costs (20%) is attributable to direct medical care costs, possible because very few
treatment options are available [1]. Direct social care (home, nursing) and informal care
costs each attribute 40% to the costs. Informal care costs are costs made by unpaid
informal care givers (such as relatives) who are for example unable to work during this
time.
Despite the fact that the societal cost of AD is substantial higher than those of stroke,
heart disease and cancer, research funding into AD is less than in these disease [4]. It is
therefore imperative that both fundamental and applied research funding is increased
to prevent an economical disaster in the coming decades. The problem is further
aggravated by the fact that there is no cure for the disease available. In addition, the
exact disease process remains vague and also diagnosis of AD is not straightforward [5].
The thesis contains both a therapeutic and a diagnostic component that offers
direct possibilities for valorization. First we will discuss possible valorization options
from a therapeutic point of view, while subsequently we will discuss diagnostic options
suggested in this thesis.
7.1. THERAPEUTIC OPPORTUNITIES
At the moment, 5 different drugs are approved for AD. Every year, about 1 billion
dollars are spent on these drugs in the USA alone [6]. While these drugs provide some
symptomatic relief for patients, they do not tackle the underlying cause of AD, and as
such, they lose their effectiveness over time.
In this thesis, immunotherapy against amyloid was investigated as a possible
treatment option. Anti-Aβ treatment has been tested in over 25 000 patients in various
clinical trials (Chapter 2). Although cost estimates are not available, these trials are likely
to represent a huge investment on the part of pharmaceutical companies. Furthermore,
there is a large societal costs and effort required both on the patient and caregiver side.
Knowledge obtained in this thesis helps to improve future immunotherapy trials and
possible increase the success rate of anti-Aβ strategies, if these strategies are further
pursued in the future.
Despite the fact that immunotherapy trials have failed so far, we show that preventive
treatment might be a viable option for the treatment of AD. One key question remains
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of course whether it will be possible to identify patients early enough. A big problem is
that amyloid pathology starts about 15-20 years before the onset of cognitive problems
[7]. It remains thus to be seen how it would be possible to select patients for possible
treatment, or if treatment starting in the state of Mild Cognitive Impairment (MCI) is
sufficient to obtain a disease modifying effect.
Our results show that there might be valorization opportunities in custom antibody
formats and effector mechanisms. In this thesis, an antibody with full effector
mechanisms (Fcγ-receptor binding and complement activation) was compared with
an antibody with no effector mechanisms. A possible valorization opportunity would
be to investigate antibodies with partial effector mechanisms (eg. only complement
activation or only Fcγ-receptor binding) and see which mechanisms is the most
important for an efficient and safe therapy. This specific modification could then
be patented. Additionally, it might also be worthwhile to investigate different, more
exotic antibody formats, such as bispecific antibodies to increase brain penetration and
increase the effective dose in the brain.
7.2. DIAGNOSTIC OPPORTUNITIES
While AD can only be diagnosed with certainty post-mortem, a number of options
are currently available for early diagnosis of the disease. As discussed in Chapter 1
of these thesis, diagnostic tools currently in common use are cognitive tests and CSF
measurements. Aβ and tau measurements in CSF are now routinely being used as part of
the neurological examination in patients with cognitive impairments. However, besides
these measures, also imaging biomarkers are being routinely used. One advantage
over imaging techniques is that they also provide additional spatial information as to
where pathology is spreading and about the severity of the pathology. While structural
Magnetic Resonance Imaging (MRI) is routinely used for diagnosis, the use of Positron
Emission Tomography (PET) to image amyloid is now finding routine use.
One of the disadvantages of current amyloid PET tracers is that they are only able to
image fibrillar Aβ deposits (plaques). However, recent experimental data suggests that it
is actually the oligomeric Aβ species which are more toxic. It would therefore be of great
diagnostic and scientific value if different Aβ species could be imaged. This thesis proves
in pre-clinical studies that this might be feasible.
The use of monoclonal antibodies radiolabeled with 89Zirconium is routinely applied
in the clinic for imaging of tumors [8]. Despite the fact that radiation dose is always a
concern with PET imaging, the technology has proven safe in humans. We, and very
recently also others, have shown that antibodies can be used for imaging amyloid in the
brain in vivo [9, 10]. This opens opportunities to try this technology in humans. Since
both the use of 89Zr and some of the antibodies we tested have already passed clinical
trials, and proven safe, amyloid immuno-PET could be tried very fast in humans. This
could provide valuable new insights in amyloid pathology in patients. In vivo imaging
using this technique in mice suffers from several drawbacks, such as the high bone
uptake of 89Zr [11]. In humans, this problem would not occur, and the technique would
therefore benefit from a higher signal-to-noise ratio.
Besides applications for diagnosis and fundamental science, immuno-PET also
offers the possibility to use monoclonal antibodies as a theranostic tool. Since several
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antibodies are still in clinical trial, this would provide a valuable addition to current
clinical trials. A theranostic is a drug that is a diagnostic tool and a therapeutic drug at the
same time. By using the same antibody that is used for therapy for imaging pathology,
target engagement can be shown on an individual patient basis. This will allow to screen
patients before inclusion in clinical trials, possibly increasing success of the trial and
preventing people with non-AD dementia from being included in the trial. Furthermore,
therapy effects could be monitored over time.
Finally, the fact that immuno-PET can be used for Aβ imaging, as we show in this
thesis, might also mean that immuno-PET can be used to target other proteins in the
CNS. Applications for immuno-PET might therefore include also other proteinopathies
such as Parkinson’s disease, for which no tracers are available for the moment.
Monoclonal antibodies against α-synuclein could be radiolabeled and used to confirm
Parkinson’s disease. Other possible disease could be for instance Prion disease, but also
in AD there are still possible targets left. Besides Aβ, also tau might prove a valuable target
to image with immuno-PET, and currently there are only few tau tracers available, and
these are still in early development. A possible caveat is that tau is intracellular, and it
remains an open question whether antibodies will be able to bind then. However, results
from a study using tau antibodies for in vivo imaging system (IVIS) imaging, shows that
this might not be such a big issue [12].
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